Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason J Luke

Showing results (61-70 of 185) with videos related to

Pageof 19
Sort By:
Journal of the National Cancer Institute|June 22, 2023
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinationsLilit Karapetyan, Uzoma K Iheagwara, Adam C Olson, et al.
JAMA Dermatology|October 17, 2014
Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockadeShirwa Sheik Ali, Allison L Goddard, Jason J Luke, et al.
Science (New York, N.Y.)|January 6, 2018
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patientsVyara Matson, Jessica Fessler, Riyue Bao, et al.
Journal for Immunotherapy of Cancer|April 6, 2018
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancerRandy F Sweis, Yuanyuan Zha, Lomax Pass, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver MetastasisDouglas B Johnson, Riyue Bao, Kristin K Ancell, et al.
Future Oncology (London, England)|February 26, 2019
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world studyJason J Luke, Sameer R Ghate, Jonathan Kish, et al.
Cancer Chemotherapy and Pharmacology|April 20, 2024
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumorsClaire Miller, Roberto Sommavilla, Cindy L O'Bryant, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2020
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and PembrolizumabMark C Korpics, Mei-Yin Polley, Sandeep R Bhave, et al.
Cancer Immunology Research|May 7, 2015
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic MelanomaJason J Luke, Hilary Donahue, Mizuki Nishino, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanomaJonathan A Trujillo, Jason J Luke, Yuanyuan Zha, et al.
Pageof 19

Showing results (61-70 of 185) with videos related to

Sort By:
Pageof 19
Journal of the National Cancer Institute|June 22, 2023
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinationsLilit Karapetyan, Uzoma K Iheagwara, Adam C Olson, et al.
JAMA Dermatology|October 17, 2014
Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockadeShirwa Sheik Ali, Allison L Goddard, Jason J Luke, et al.
Science (New York, N.Y.)|January 6, 2018
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patientsVyara Matson, Jessica Fessler, Riyue Bao, et al.
Journal for Immunotherapy of Cancer|April 6, 2018
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancerRandy F Sweis, Yuanyuan Zha, Lomax Pass, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver MetastasisDouglas B Johnson, Riyue Bao, Kristin K Ancell, et al.
Future Oncology (London, England)|February 26, 2019
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world studyJason J Luke, Sameer R Ghate, Jonathan Kish, et al.
Cancer Chemotherapy and Pharmacology|April 20, 2024
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumorsClaire Miller, Roberto Sommavilla, Cindy L O'Bryant, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2020
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and PembrolizumabMark C Korpics, Mei-Yin Polley, Sandeep R Bhave, et al.
Cancer Immunology Research|May 7, 2015
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic MelanomaJason J Luke, Hilary Donahue, Mizuki Nishino, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanomaJonathan A Trujillo, Jason J Luke, Yuanyuan Zha, et al.
Pageof 19